ANI Pharmaceuticals VP Sells 500 Shares Under 10b5-1 Plan

Meredith Cook, VP of ANI Pharmaceuticals, executed a third consecutive quarterly sale of 500 shares, reducing direct ownership by 0.67% to 73,924 shares.
Meredith Cook, Vice President of ANI Pharmaceuticals, Inc. (NASDAQ: ANIP), sold 500 shares of company stock on September 14. The transaction valued at $35,395, with shares averaging $70.79 each, reduced Cook’s direct holdings to 73,924 shares. This sale represents a 0.67% decrease in personal ownership and was executed under a pre-arranged Rule 10b5-1 trading plan, as disclosed in SEC filings.
This sale follows a consistent pattern of quarterly disposals by the executive. Cook sold 500 shares in August at an average price of $75.48 and another 500 in July at $81.84. The sequential decline in sale prices mirrors the broader trend in the company’s stock, which has traded below its 50-day moving average of $76.97 and 200-day moving average of $78.17.
Recent Financial Performance Beats Estimates
ANI Pharmaceuticals reported second-quarter earnings on August 7, posting an EPS of $2.21, which exceeded the consensus estimate of $2.04 by $0.17. Revenue reached $266.04 million, surpassing the expected $260.13 million and marking a 25.8% year-over-year increase. The company achieved a net margin of 11.07% and a return on equity of 27.37%, indicating strong operational efficiency relative to prior periods.
Forward Guidance Exceeds Street Projections
Management has set full-year 2026 guidance for EPS between $9.19 and $9.69. This range sits above the current fiscal year analyst consensus of $7.83, suggesting the company expects sustained growth in profitability. The guidance reflects confidence in the specialty pharmaceutical portfolio’s ability to maintain margin expansion and revenue momentum throughout the upcoming year.
Institutional Investors Increase Holdings
Despite the insider sale, institutional interest in ANIP has intensified. The California State Teachers Retirement System increased its stake by 7,977.4% in Q2, acquiring nearly 2 million shares. Other institutions, including Arrowstreet Capital and Dimensional Fund Advisors, also raised their positions in Q1. Institutional investors now hold 76.05% of the company’s shares, indicating a significant divergence between insider activity and large-fund accumulation strategies.






